AUPN115095A0 - Analysis of and compositions and methods for the treatment of disease - Google Patents

Analysis of and compositions and methods for the treatment of disease

Info

Publication number
AUPN115095A0
AUPN115095A0 AUPN1150A AUPN115095A AUPN115095A0 AU PN115095 A0 AUPN115095 A0 AU PN115095A0 AU PN1150 A AUPN1150 A AU PN1150A AU PN115095 A AUPN115095 A AU PN115095A AU PN115095 A0 AUPN115095 A0 AU PN115095A0
Authority
AU
Australia
Prior art keywords
disease
compositions
analysis
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN1150A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klineberg Iven John
Roberts Timothy Kilgour
Newcastle Innovation Ltd
Original Assignee
Butt H L
DUNSTAN R H
Klineberg I J
Mcgregor N R
Roberts T K
ZERBES M
Newcastle Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Butt H L, DUNSTAN R H, Klineberg I J, Mcgregor N R, Roberts T K, ZERBES M, Newcastle Innovation Ltd filed Critical Butt H L
Priority to AUPN1150A priority Critical patent/AUPN115095A0/en
Publication of AUPN115095A0 publication Critical patent/AUPN115095A0/en
Priority to PCT/IB1996/000222 priority patent/WO1996025155A1/en
Priority to AU48412/96A priority patent/AU4841296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
AUPN1150A 1995-02-15 1995-02-15 Analysis of and compositions and methods for the treatment of disease Abandoned AUPN115095A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPN1150A AUPN115095A0 (en) 1995-02-15 1995-02-15 Analysis of and compositions and methods for the treatment of disease
PCT/IB1996/000222 WO1996025155A1 (en) 1995-02-15 1996-02-15 Diagnosis of and compositions and methods for the treatment of disease
AU48412/96A AU4841296A (en) 1995-02-15 1996-02-15 Diagnosis of and compositions and methods for the treatment of disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN1150A AUPN115095A0 (en) 1995-02-15 1995-02-15 Analysis of and compositions and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
AUPN115095A0 true AUPN115095A0 (en) 1995-03-09

Family

ID=3785508

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPN1150A Abandoned AUPN115095A0 (en) 1995-02-15 1995-02-15 Analysis of and compositions and methods for the treatment of disease
AU48412/96A Abandoned AU4841296A (en) 1995-02-15 1996-02-15 Diagnosis of and compositions and methods for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU48412/96A Abandoned AU4841296A (en) 1995-02-15 1996-02-15 Diagnosis of and compositions and methods for the treatment of disease

Country Status (2)

Country Link
AU (2) AUPN115095A0 (en)
WO (1) WO1996025155A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548221C1 (en) * 1995-12-22 1997-05-15 Biotest Pharma Gmbh Oral use of immunoglobulin preparations for the treatment and prophylaxis of chronic pain
SE9604844D0 (en) * 1996-12-30 1996-12-30 Carl Gerhard Gottfries Agents for the therapeutic treatment of fibromyalgia and chronic fatigue syndrome
SE523136C2 (en) * 1999-12-21 2004-03-30 Gottfriesmottagningen Ab Use of staphylococcal bacteria in the treatment of irritable bowel syndrome
DE102011006809A1 (en) * 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Use of an agent of antibodies and / or insulin-like growth factor antagonists
DE102011006781A1 (en) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antibody product comprising n specific antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6901M (en) * 1967-06-23 1969-04-28
DE3034975C2 (en) * 1980-09-17 1986-11-27 Dr. Karl Thomae Gmbh, 7950 Biberach Drug combination used to treat infectious respiratory diseases
US4532206A (en) * 1982-07-19 1985-07-30 Vitek Systems, Inc. β-Streptococcus selective medium
JPS60218396A (en) * 1984-04-16 1985-11-01 Shionogi & Co Ltd Antibiotic do-248-a and do-248-b and preparation thereof
US4992365A (en) * 1984-04-23 1991-02-12 Hyman Edward S Method of detecting bacteria in urine
GB8426463D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
EP0206625B1 (en) * 1985-06-13 1992-09-30 Barry James Dr. Marshall Compositions for the treatment of gastrointestinal disorders
US4950589A (en) * 1987-08-10 1990-08-21 Akzo N.V. Genus-specific listeria antigen identified by monoclonal antibodies
EP0313846B1 (en) * 1987-10-29 1994-05-04 American Cyanamid Company Method for controlling chronic respiratory disease, and necrotic enteritis in avian species
JPH03503887A (en) * 1988-02-03 1991-08-29 エクソウマ　コーポレーション Therapeutic use of anti-T cell immunotoxins for autoimmune diseases
AU3834889A (en) * 1988-05-25 1989-12-12 Edward S. Hyman Detecting bacteria in urine of horses
CA1339775C (en) * 1988-06-10 1998-03-24 Shuzo Matsushita Antibody 0.5b to hiv-i gp 120 modified with toxic substance
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
RU2005487C1 (en) * 1989-06-26 1994-01-15 Научная фирма "Биосиб" Method for treating bronchopulmonary diseases
JPH03112494A (en) * 1989-09-26 1991-05-14 Takehisa Akiyama Monoclonal antibody, diagnosing reagent and assaying method using the same antibody
JP2534139B2 (en) * 1989-10-09 1996-09-11 株式会社大塚製薬工場 Oral amino acid preparation for renal failure
AU3328293A (en) * 1991-12-24 1993-07-28 Stephen Herman Medical uses of trioxolane and diperoxide compounds
DE4201988C2 (en) * 1992-01-25 1994-03-03 Pulverer Gerhard DNA probe to identify Staphylococcus haemolyticus
GB2266526A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfones useful in the treatment of leukemia
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
JPH06242115A (en) * 1993-02-12 1994-09-02 Hideo Igarashi Inspection method and inspection kit for a group streptococcus pyrogenic toxin and/or rubefaction toxin
DE69428041T2 (en) * 1993-05-03 2002-03-28 Genentech Inc Inhibition of leukocyte adhesion
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
KR0139235B1 (en) * 1994-01-29 1998-04-28 조세현 Cement bead composition for orthopaedic surgery and its manufacturing process
ATE182793T1 (en) * 1994-02-18 1999-08-15 Immuno Ag COMPOSITION AND METHOD FOR PREVENTING AND TREATING INFLAMMATION WITH IMMUNOGLOBIN A
IT1272290B (en) * 1994-06-20 1997-06-16 Avantgarde Spa SALT OF L-CARNITINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT FOR THE TREATMENT OF SKIN DISEASES
HU215443B (en) * 1994-07-25 1999-04-28 Márton Milánkovits Pharmaceutical compositions, first of all vaginal suppositorium, containing more active components with bactericide, fungicide, antiprotozoonic and antiviral combined activity

Also Published As

Publication number Publication date
WO1996025155A1 (en) 1996-08-22
AU4841296A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
EP0808324A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU5439996A (en) Compositions and methods for treating pain
AU5268696A (en) Novel compounds and methods for therapy
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU1136297A (en) Methods and compositions for diagnosis of hyperhomocysteinemia
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU6328696A (en) Treatment of hemoglobinopathies
EP0761718A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU2821295A (en) Compositions and methods for the treatment of tumors
AU5631096A (en) Antihistamine-wound healing compositions and methods for pre paring and using same
EP0761721A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
AU1831195A (en) Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AUPN115095A0 (en) Analysis of and compositions and methods for the treatment of disease
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders
AU5526196A (en) Compositions for the treatment of dandruff
AU5699396A (en) Compositions for the treatment of skin conditions